Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atazanavir/Ritonavir vs Lopinavir/Ritonavir in HIV-1 Virologic Failure
NCT00135395Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2004
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of atazanavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Viral load reduction from baseline at 24 weeks and Change in serum lipids from baseline at 12 weeks. Started May 2004; status: completed.
02
Drugs
atazanavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00135395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135395.